Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Elias Angelopoulos1, Christos Theleritis1, Marina Economou1

  • 11st Department Psychiatry, Aiginition Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Pharmacopsychiatry
|May 17, 2017
PubMed
Summary

Treatment-resistant schizophrenia (TRS) in 22q11.2 deletion syndrome patients may respond to clozapine. This case study highlights clozapine as a crucial option for psychosis management in this population.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing Hemophilia Care: Real-World Outcomes Following Switching to Extended Half-Life Factor VIII in Greece-The TOOL Study.

Life (Basel, Switzerland)·2026
Same author

Tardive Oromandibular Dystonia Associated With Long-Term Intermittent Use of Lurasidone.

Journal of clinical psychopharmacology·2026
Same author

Disease burden and unmet medical need in severe hemophilia in Greece: insights from clinicians and patients.

Frontiers in public health·2026
Same author

Hemophilia's Overlooked Female Face.

Journal of clinical medicine·2026
Same author

Managing Dual Diagnosis Patients and the Importance of Assessing Capacity: Data from London Inpatient Services.

Brain sciences·2025
Same author

Janus kinase/signal transducer and activator of transcription pathway in schizophrenia (Review).

Biomedical reports·2025

Area of Science:

  • Psychiatry
  • Medical Genetics
  • Pharmacology

Background:

  • 22q11.2 deletion syndrome is associated with an increased risk of psychosis.
  • Optimal pharmacological treatment for 22q11.2 deletion syndrome-related psychoses remains a focus of research.
  • Treatment-resistant schizophrenia (TRS) presents significant management challenges.

Observation:

  • A 23-year-old Cypriot patient with 22q11.2 deletion syndrome presented with TRS.
  • The patient underwent sequential treatment with multiple antipsychotic medications including aripiprazole, risperidone, olanzapine, haloperidol, and a combination of olanzapine and haloperidol.
  • These treatments failed to adequately manage the patient's psychotic symptoms.

Findings:

  • Clozapine was administered as a last resort due to treatment resistance.

Related Experiment Videos

  • Clozapine monotherapy resulted in significant improvement of the patient's psychotic condition.
  • This indicates clozapine's efficacy in a specific case of 22q11.2 deletion syndrome-related TRS.

    • Implications:

    • Clozapine should be considered as a viable treatment option for individuals with 22q11.2 deletion syndrome and TRS.
    • Further research is warranted to explore the role of clozapine in managing psychoses associated with 22q11.2 deletion syndrome.
    • This case contributes to understanding the pharmacotherapy for rare genetic disorders with psychiatric manifestations.